We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).

We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.

Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.

Advanced search
Date range (dd-mm-yyyy)

Allergy Therapeutics

Start of pivotal Grass MATA MPL Phase III trial

Lighthouse | 08 December 2022

HUTCHMED

A sharper focus on the path to profitability

Lighthouse | 21 November 2022

HUTCHMED

Fruquintinib should continue to bear fruit

Lighthouse | 21 November 2022

Arecor Therapeutics

Specialty Hospital products formulation collaboration

Lighthouse | 10 November 2022

Futura Medical

On the cusp of MED3000 commercialisation

Update | 10 November 2022

Scancell

FY22 results highlight clinical and corporate progress

Lighthouse | 28 October 2022

Allergy Therapeutics

Manufacturing pause takes it toll on revenues

Update | 28 October 2022

Scancell

Optimum partner secured for first antibody deal

Lighthouse | 25 October 2022

Avacta

Diagnostics M&A-led growth strategy is ready to Launch

Lighthouse | 18 October 2022

Arecor Therapeutics

AT247 Phase I pump data confirms promising profile

Lighthouse | 11 October 2022
< 2 3 4 5 6 7 8 9 10 11 >
397 results found.